Is aspirin ″the weakest link” in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease
- 28 February 2002
- journal article
- review article
- Published by Elsevier in Progress in Cardiovascular Diseases
- Vol. 44 (4) , 275-292
- https://doi.org/10.1053/pcad.2002.31597
Abstract
No abstract availableKeywords
This publication has 98 references indexed in Scilit:
- Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT studyJournal Of Hypertension, 2000
- Final Report on the Aspirin Component of the Ongoing Physicians' Health StudyNew England Journal of Medicine, 1989
- Clinical pharmacology of platelet cyclooxygenase inhibition.Circulation, 1985
- Dose-Related Kinetics of AspirinNew England Journal of Medicine, 1984
- Incidence and Prognosis of Unrecognized Myocardial InfarctionNew England Journal of Medicine, 1984
- Renal Syndromes Associated with Nonsteroidal Antiinflammatory DrugsNew England Journal of Medicine, 1984
- Prostaglandins in Severe Congestive Heart FailureNew England Journal of Medicine, 1984
- Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable AnginaNew England Journal of Medicine, 1983
- Differential Inhibition by Aspirin of Vascular and Platelet Prostaglandin Synthesis in Atherosclerotic PatientsNew England Journal of Medicine, 1983
- Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group.Circulation, 1980